Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05435846 | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | terminated | Phase 1 | 3 | Collin BlakelyOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02309892 | A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | terminated | Phase 1 | 14 | Helix BioPharma CorporationINDUSTRY | 1 | Jun 3, 2024 | clinicaltrials |
| NCT02635061 |
| Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer |
| terminated |
| Phase 1 |
| 17 |
| CelgeneINDUSTRY |
| 1 |
| May 7, 2024 |
| clinicaltrials |
| NCT04476797 | Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC(GRECO-1) | terminated | Phase 1 / Phase 2 | 47 | Galera Therapeutics, Inc.INDUSTRY | 1 | Apr 30, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | terminated | Phase 1 | 13 | PfizerINDUSTRY | 1 | Apr 12, 2024 | clinicaltrials |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 127 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 86 | Ikena OncologyINDUSTRY | 1 | Mar 22, 2024 | clinicaltrials |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | terminated | Phase 1 | 31 | Mersana TherapeuticsINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | terminated | Phase 1 / Phase 2 | 11 | NKGen Biotech, Inc.INDUSTRY | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study(PIL) | terminated | Phase 1 / Phase 2 | 4 | Asha NayakOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy(FLT3) | terminated | Phase 1 / Phase 2 | 5 | Albert Einstein College of MedicineOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04524195 | PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05088967 | Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer | terminated | Phase 1 | 6 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT03386929 | Survival Prolongation by Rationale Innovative Genomics(SPRING) | terminated | Phase 1 / Phase 2 | 15 | Worldwide Innovative Network AssociationOTHER | 4 | Dec 18, 2023 | clinicaltrials |
| NCT04739358 | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | terminated | Phase 1 / Phase 2 | 2 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03317496 | Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 67 | PfizerINDUSTRY | 8 | Aug 29, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT02919449 | Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | terminated | Phase 1 | 2 | Vyriad, Inc.INDUSTRY | 1 | Jul 21, 2023 | clinicaltrials |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | terminated | Phase 1 | 23 | AvenCell Europe GmbHINDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02584634 | Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | terminated | Phase 1 / Phase 2 | 43 | PfizerINDUSTRY | 5 | Jul 7, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT05153408 | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | terminated | Phase 1 | 20 | Blueprint Medicines CorporationINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT03509584 | Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients | terminated | Phase 1 | 6 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas | terminated | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | May 31, 2023 | clinicaltrials |
| NCT04849273 | A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC | terminated | Phase 1 | 11 | Turning Point Therapeutics, Inc.INDUSTRY | 3 | May 26, 2023 | clinicaltrials |
| NCT02382406 | Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | terminated | Phase 1 / Phase 2 | 46 | Nisha Mohindra, MDOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03275597 | Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition | terminated | Phase 1 | 17 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02961283 | Study of ASN003 in Subjects With Advanced Solid Tumors | terminated | Phase 1 | 24 | Asana BioSciencesINDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT01912625 | Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | May 6, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | terminated | Phase 1 | 88 | Seagen Inc.INDUSTRY | 5 | Mar 23, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03138889 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors(PROPEL) | terminated | Phase 1 / Phase 2 | 162 | Nektar TherapeuticsINDUSTRY | 5 | Mar 10, 2023 | clinicaltrials |
| NCT03265080 | A Study of ADXS-NEO Expressing Personalized Tumor Antigens(NEO) | terminated | Phase 1 | 13 | Advaxis, Inc.INDUSTRY | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04622072 | XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 1 | 21 | Sihuan Pharmaceutical Holdings Group Ltd.INDUSTRY | 1 | Feb 17, 2023 | clinicaltrials |
| NCT03656627 | Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease | terminated | Phase 1 | 7 | Alliance Foundation Trials, LLC.OTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT03663166 | Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT03599518 | DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 8, 2023 | clinicaltrials |
| NCT04297748 | Bioimaging Study of 89Zr-M7824 in NSCLC | terminated | Phase 1 / Phase 2 | 5 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jan 17, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2024source: clinicaltrials